Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.46 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.46 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.45 |
| ▸ | PYGL | P06737 | 8/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6717632 | 0.91 | ATM (0.47) | ALDH1A1CXCL8HSP90AA1ATMGAA | |
| SCHEMBL6717585 | 0.85 | TP53 (0.46) | — | |
| SCHEMBL6716822 | 0.84 | KCNQ2 (0.56) | ALDH1A1PDK1PDK2PDK3PDK4 | |
| SCHEMBL6716835 | 0.82 | CYP1A2 (0.48) | ALDH1A1PDK1PDK2PDK3PDK4 | |
| SCHEMBL6716842 | 0.82 | CYP1A2 (0.48) | ALDH1A1PDK1PDK2PDK3PDK4 | |
| SCHEMBL6719501 | 0.81 | MAPT (0.46) | ALDH1A1CYP3A4CYP2C19PTGS2MAPK14 | |
| SCHEMBL6716823 | 0.80 | KCNJ11 (0.40) | ALDH1A1GAACYP3A4CYP2C19 | |
| SCHEMBL6716791 | 0.79 | ALDH1A1 (0.49) | ALDH1A1GAA | |
| SCHEMBL6723623 | 0.78 | POLB (0.51) | ALDH1A1HSP90AA1ATMGAA | |
| SCHEMBL6713979 | 0.78 | ALDH1A1 (0.53) | ALDH1A1HSP90AA1ATMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | NPS ALLELIX CORPORATION (CA) | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152740-A1 | Arylglycine derivatives for use as glycine transport inhibitors | SLC1A2, SLC6A7, SLC1A1 | ALDH1A1 572/4885PDK1 2368/4885PDK2 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.